PAR-22-181 - NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
NOT-NS-22-111 - Notice of Change to the title of PAR-22-181 "NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)"
National Institute of Nursing Research (NINR)
National Institute of Neurological Disorders and Stroke (NINDS)
This Notice informs potential applicants of the National Institute of Nursing Research (NINR) participation, effective immediately, in the funding opportunity announcement (FOA) PAR-22-181, “NIDA, NIMH, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional).”
The following sections of PAR-22-181 have been modified to reflect the NINR's participation in this FOA:
Components of Participating Organizations
Currently Reads:
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
Modified to Read (changes shown in bold italics):
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
Assistance Listing Number(s)
Currently Reads:
93.853, 93.279, 93.242
Modified to Read (changes shown in bold italics):
93.853, 93.279, 93.242, 93.361
Section I. Funding Opportunity Description
Specific Areas of Research Interest:
Currently Reads:
NIDA
NIDA will support applications that address or seek fundamental knowledge related to addiction sciences, including, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, development of new and improved strategies to prevent substance use and its consequences, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, HIV and drugs of abuse (including basic discovery science research as well as applied research on delivery of HIV and substance use prevention and treatment services to persons who use drugs), medication development, epidemiology, identifying the biological, environmental, behavioral, and social causes and consequences of substance use and addiction across the lifespan, and implementation science, including secondary data analysis. In all these and related areas of addiction sciences research, NIDA encourages an emphasis on understanding and addressing health disparities which are experienced by vulnerable populations. Only applications that fall within the scientific mission of NIDA will be considered for funding (https://nida.nih.gov/about-nida/strategic-plan/directors-message).
NIMH
The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH supports research on topics that include basic neuroscience and behavioral science, and translational application of brain and behavior relationships in healthy and diseased states. Mental disorders may be defined according to existing diagnostic criteria or along dimensions of neurobehavioral functioning according to the NIMH Research Domain Criteria (RDoC) framework. If existing diagnostic criteria are to be used, investigators should include plans for addressing heterogeneity within the diagnostic category or categories. Applications considered for funding by the NIMH must fall within the areas of priority detailed in the NIMH Strategic Plan and the NIMH Strategic Research Priorities. It is recommended that investigators contact NIMH Scientific/Research staff well in advance of submitting applications to discuss the match to NIMH priorities. NIMH supports mechanistic clinical trials that focus on biomarker studies that may provide information about physiological function, target engagement of therapeutics, and/or the impact of therapeutic responses. These types of studies do not have as a primary aim to establish the efficacy or effectiveness of the intervention.
NIMH considers two major categories of mechanistic trials (though there may be others):
-
Mechanistic clinical trials using an intervention of known efficacy. These clinical trials utilize an efficacious intervention to investigate the pathophysiology, and/or psychopathology of mental disorders or the mechanisms of therapeutic responses; and to advance biomarkers of basic neurobiological processes. In such studies: (1) the primary aims do not involve establishing efficacy/effectiveness, and (2) the intervention chosen has already been demonstrated to have efficacy.
-
Mechanistic clinical trials utilizing an experimental manipulation: These studies utilize experimental manipulation and are primarily focused on understanding brain function in healthy individuals or those with mental disorders by measuring responses to the experimental manipulation. They are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.
See the “Consolidated Notice on NIMH Clinical Trials Policies,”NOT-MH-20-105, for a summary of NIMH’s polices on support for mechanistic clinical trials.
NINDS
NINDS will support applications that address or seek fundamental knowledge about the brain and nervous system by supporting and conducting research on the healthy and diseased brain, spinal cord, and peripheral nerves and to use that knowledge to reduce the burden of neurological disease. NINDS supports basic, translational, and clinical research. NINDS also encourages activities focused on understanding and addressing disparities in neurologic health, healthcare, and health outcomes in disparate populations, including racial and ethnic minorities, the geographically disadvantaged, sex and gender minorities, and others who have been historically underserved, marginalized, and adversely affected by persistent inequality and socioeconomic disadvantage.
Only applications that fall within the scientific mission of the NINDS will be considered for funding(https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission) and the NINDS Strategic Plan (https://www.ninds.nih.gov/About-NINDS/Strategic-Plans-Evaluations/Strategic-Plans/NINDS-Strategic-Plan-and-Priorities/Neuroscience-Research).
Modified to Read (changes shown in bold italics):
NIDA
NIDA will support applications that address or seek fundamental knowledge related to addiction sciences, including, but not limited to: cellular and molecular neuroscience, neuroimaging, genetics, medication and treatment development, development of new and improved strategies to prevent substance use and its consequences, neuroimmune signaling, neuropathology in brain systems, cognitive processes, population neuroscience, HIV and drugs of abuse (including basic discovery science research as well as applied research on delivery of HIV and substance use prevention and treatment services to persons who use drugs), medication development, epidemiology, identifying the biological, environmental, behavioral, and social causes and consequences of substance use and addiction across the lifespan, and implementation science, including secondary data analysis. In all these and related areas of addiction sciences research, NIDA encourages an emphasis on understanding and addressing health disparities which are experienced by vulnerable populations. Only applications that fall within the scientific mission of NIDA will be considered for funding (https://nida.nih.gov/about-nida/strategic-plan/directors-message).
NIMH
The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. NIMH supports research on topics that include basic neuroscience and behavioral science, and translational application of brain and behavior relationships in healthy and diseased states. Mental disorders may be defined according to existing diagnostic criteria or along dimensions of neurobehavioral functioning according to the NIMH Research Domain Criteria (RDoC) framework. If existing diagnostic criteria are to be used, investigators should include plans for addressing heterogeneity within the diagnostic category or categories. Applications considered for funding by the NIMH must fall within the areas of priority detailed in the NIMH Strategic Plan and the NIMH Strategic Research Priorities. It is recommended that investigators contact NIMH Scientific/Research staff well in advance of submitting applications to discuss the match to NIMH priorities. NIMH supports mechanistic clinical trials that focus on biomarker studies that may provide information about physiological function, target engagement of therapeutics, and/or the impact of therapeutic responses. These types of studies do not have as a primary aim to establish the efficacy or effectiveness of the intervention.
NIMH considers two major categories of mechanistic trials (though there may be others):
-
Mechanistic clinical trials using an intervention of known efficacy. These clinical trials utilize an efficacious intervention to investigate the pathophysiology, and/or psychopathology of mental disorders or the mechanisms of therapeutic responses; and to advance biomarkers of basic neurobiological processes. In such studies: (1) the primary aims do not involve establishing efficacy/effectiveness, and (2) the intervention chosen has already been demonstrated to have efficacy.
-
Mechanistic clinical trials utilizing an experimental manipulation: These studies utilize experimental manipulation and are primarily focused on understanding brain function in healthy individuals or those with mental disorders by measuring responses to the experimental manipulation. They are not intended to inform on the improvement of the health status of the individual or a group of individuals either by better understanding the mechanism of action of an intervention or a measurable improvement in health.
See the “Consolidated Notice on NIMH Clinical Trials Policies,”NOT-MH-20-105, for a summary of NIMH’s polices on support for mechanistic clinical trials.
NINDS
NINDS will support applications that address or seek fundamental knowledge about the brain and nervous system by supporting and conducting research on the healthy and diseased brain, spinal cord, and peripheral nerves and to use that knowledge to reduce the burden of neurological disease. NINDS supports basic, translational, and clinical research. NINDS also encourages activities focused on understanding and addressing disparities in neurologic health, healthcare, and health outcomes in disparate populations, including racial and ethnic minorities, the geographically disadvantaged, sex and gender minorities, and others who have been historically underserved, marginalized, and adversely affected by persistent inequality and socioeconomic disadvantage.
Only applications that fall within the scientific mission of the NINDS will be considered for funding (https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission) and the NINDS Strategic Plan (https://www.ninds.nih.gov/About-NINDS/Strategic-Plans-Evaluations/Strategic-Plans/NINDS-Strategic-Plan-and-Priorities/Neuroscience-Research).
NINR
The National Institute of Nursing Research (NINR) supports research to solve pressing health challenges and inform practice and policy - optimizing health and advancing health equity into the future. NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care. Only applications that fall within these areas as detailed in the NINR 2022–2026 Strategic Plan will be considered. Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses work, including homes, schools, workplaces, clinics, justice settings, and the community. Observational, intervention, and implementation research are of interest.
Section II. Award Information
Funds Available and Anticipated Number of Awards
Currently Reads:
The following NIH components intend to commit the following amounts for the duration of this PAR:
NINDS intends to commit up to $10 million per fiscal year, approximately 25 awards, dependent on award amounts
NIDA intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NIMH intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
Future year amounts will depend on annual appropriations.
Modified to Read (changes shown in bold italics):
The following NIH components intend to commit the following amounts for the duration of this PAR:
NINDS intends to commit up to $10 million per fiscal year, approximately 25 awards, dependent on award amounts
NIDA intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NIMH intends to commit up to $5 million per fiscal year, 12-15 awards, dependent on award amounts
NINR intends to commit up to $1 million per fiscal year, 2-3 awards, dependent on award amounts
Future year amounts will depend on annual appropriations.
Section VII. Agency Contacts
Scientific/Research Contact(s)
Currently Reads:
Albert Avila, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email: NINDSDiversityTraining@mail.nih.gov
Lauren D. Hill, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-2638
Email: hillla@mail.nih.gov
Modified to Read (changes shown in bold italics):
Albert Avila, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-8804
Email: aavila@nida.nih.gov
Michelle Jones-London, Ph.D.
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-451-7966
Email: NINDSDiversityTraining@mail.nih.gov
Lauren D. Hill, PhD
National Institute of Mental Health (NIMH)
Telephone: 301-443-2638
Email: hillla@mail.nih.gov
Shalanda A. Bynum, PhD, MPH
National Institute of Nursing Research (NINR)
Telephone: 301-755-4355
Email: shalanda.bynum@nih.gov
Financial/Grants Management Contact(s)
Currently Reads:
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8927
Email: pfleming@nida.nih.gov
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov
Terri Jarosik
National Institute of Mental Health (NIMH)
Telephone: 301-443-3858
Email: tjarosik@mail.nih.gov
Modified to Read (changes shown in bold italics):
Pamela Fleming
National Institute on Drug Abuse (NIDA)
Telephone: 301-253-8927
Email: pfleming@nida.nih.gov
Chief Grants Management Officer
National Institute of Neurological Disorders and Stroke (NINDS)
Email: ChiefGrantsManagementOfficer@ninds.nih.gov
Terri Jarosik
National Institute of Mental Health (NIMH)
Telephone: 301-443-3858
Email: tjarosik@mail.nih.gov
Kelli Oster
National Institute of Nursing Research (NINR)
Telephone: 301-594-2177
Email: osterk@mail.nih.gov
Shalanda A. Bynum, PhD, MPH
National Institute of Nursing Research (NINR)
Telephone: 301-755-4355
Email: shalanda.bynum@nih.gov
and Human Services (HHS)
